Core Insights - BioAtla, Inc. and GATC Health Corp. announced a special purpose vehicle (SPV) transaction to advance ozuriftamab vedotin (Oz-V) in a Phase 3 study for 2L+ oropharyngeal squamous cell carcinoma (OPSCC) [1][4] Financial Aspects - BioAtla will receive an initial funding of $5 million for operational and clinical trial expenses, with an additional $35 million expected to close in Q1 2026 [2][3] - Inversagen AI, LLC will hold a 35% ownership stake in Oz-V, while BioAtla retains 65% ownership across all indications after the transaction [3][8] Clinical Development - The Phase 3 trial for Oz-V is anticipated to begin enrollment in early 2026, with a clear path for potential accelerated approval in the US [4][6] - Oz-V targets ROR2, a receptor linked to tumor progression and cellular senescence, with potential applications extending to HPV-positive cancers, representing a market opportunity exceeding $7 billion globally [7][9] Strategic Collaboration - BioAtla and GATC Health plan to collaborate with Inversagen AI for the research and development of CAB senolytic therapies, maintaining rights to cancer therapeutic applications [3][5] - The partnership aims to leverage BioAtla's CAB platform technology to enhance the precision of senolytic therapies, addressing chronic inflammation and tumor progression [5][11] Technology Overview - The CAB technology developed by BioAtla is designed to selectively target diseased tissues in inflammatory conditions, enhancing therapeutic efficacy while minimizing toxicity [11][12] - ROR2-targeting agents may represent a new class of senolytics, potentially improving tissue function and reducing chronic inflammation [10]